Compare FMC Corp (FMC) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs 10X Genomics Inc — how do they compare? FMC Corp trades at $10.48 (market cap $1.31B), while 10X Genomics Inc trades at $58.51 (market cap $7.64B). The key difference: 10X Genomics Inc is far larger — about 5.8× FMC Corp's market cap, and FMC Corp pays a 3.06% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| FMC | TXG | |
|---|---|---|
Market Cap | $1.31B | $7.64B |
Sector | Basic Materials | Health |
52-Week High | $40.69 | $58.57 |
52-Week Low | $10.01 | $11.34 |
Enterprise Value | $5.11B | $7.17B |
Dividend Yield | 3.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC trades at $10.59, up 0.38% today, with a bearish technical signal from moving averages. The stock shows mixed earnings beats but faces severe profitability challenges, with a net income margin of -84.83% and negative ROE of -91.47% for 2025. Recent news highlights revenue declines and cost management efforts, including a $400 million investment from Tessenderlo Group to reduce debt.
The outlook remains cautious due to persistent losses and competitive pressures in agricultural sciences. Upside exists if operational improvements and debt reduction stabilize finances, but high volatility and margin pressures pose significant risks to shareholder value.
TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.
The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
